Mitroselect® Benefits Colon Cancer

MILAN, ItalyPharmacological and clinical data for colorectal carcinoma chemoprevention on Indenas standardized bilberry extract Mirtoselect® were presented by professor Andreas Gescher from the University of Leicester, United Kingdom, at the 51st Annual Meeting of the Italian Cancer Society (SIC) in Sesto San Giovanni, Milan, Nov. 23 to 24, during the session of Dietary Supplements and Nutraceuticals in the Management of Cancer.

A total of25 patients with colorectal cancer (and scheduled to undergo resection of primary tumor or liver metastasis) received Mirtoselect 1.4, 2.8 and 5.6 g/d for seven days before surgery. Anthocyanins and metabolites were measured in plasma and colorectal tissue. Mirtoselect reduced tumor proliferation in colorectal tumor samples taken from all patients who received the product by 7 percent compared with pre-intervention values.